Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up

Andrew J. Portuguese(University of Washington), Jordan Gauthier(Seattle Cancer Care Alliance), Ryan Basom(Fred Hutch Cancer Center), Erik L. Kimble(University of Washington), David G. Maloney(Fred Hutch Cancer Center), Qian Wu(Cancer Research Center), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Mazyar Shadman(University of Washington), Christina Poh(University of Washington), Filippo Milano(Fred Hutch Cancer Center), Lorenzo Iovino(University of Pisa), Folashade Otegbeye(University Hospitals of Cleveland), Aya Albittar(University of Washington), Ryan D. Cassaday(University of Washington), Emily C. Liang(Fred Hutch Cancer Center), Mahnoosh Taheri(Washington State University), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jennifer J. Huang(Stanford Medicine), Yein Jeon(University of Washington)
Haematologica
March 13, 2025
10.3324/haematol.2024.287010
Cited by 4

Related Papers

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603